Response Genetics Inc. (RGDX) is in the Pharma Industry

• Sort by

• Response Genetics, Inc. Update Call Transcript

  Response Genetics, Inc. Update Call Transcript

  Earnings calls 2008-03-26

  Tags: Response Genetics Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

Additional Resources

• Wall Street Media Presents Exclusive Videos from the Collins Stewart Conference and the T. Boone Pickens Press Conference

  NEW YORK -- Wall Street Media is presenting an exclusive highlight video from the presentation of Ms. Kathleen Danenberg, President and CEO of Response Genetics, Inc., (NASDAQ: RGDX), at the Collins Stewart Fourth Annual Growth Conference, held on July 8-10, 2008 at the Mandarin Oriental Hotel in New York City....

  Articles 2008-07-09

• Response Genetics, Inc. to Present at the Collins Stewart Fourth Annual Growth Conference

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ:RGDX) today announced that its president and CEO, Kathleen Danenberg, will provide a business overview, including an update on its ResponseDXTM PCR-based genetic tests, at the Collins Stewart Fourth Annual Growth Conference at the Mandarin Oriental Hotel in New York City on July 8-10....

  Articles 2008-07-08

• Response Genetics, Inc. to Hold Annual Meeting of Shareholders Tuesday, June 17, 2008 at 1:00 pm EDT

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ:RGDX) today announced that it will hold its Annual Meeting of stockholders on Tuesday, June 17, 2008, beginning at 1 p.m. EDT. The items for consideration at the meeting are included in the Proxy Statement, which has been mailed to shareholders of...

  Articles 2008-06-16

• Genetic factors in drug metabolism

  Patients vary widely in their response to drugs. Having an understanding of the pharmacokinetic and pharmacodynamic properties of various medications is important when assessing ethnic differences in drug response. Genetic factors can account for 20 to 95 percent of patient variability. Genetic polymorphisms for many drug-metabolizing enzymes and drug targets...

  Articles 2008-06-01

• David M. Jackson, Ph.D. Joins Response Genetics, Inc. as Executive Vice President

  LOS ANGELES -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of David M. Jackson, Ph.D. as the company's executive vice president. He will be responsible for planning and executing business development efforts concerning both the...

  Articles 2008-05-30

• Response Genetics, Inc. to Announce Pancreatic, Colon and Gastric Cancer Results at the 2008 American Society of Clinical Oncology Annual Meeting

  LOS ANGELES -- Response Genetics, Inc. (Nasdaq:RGDX) will announce the results of studies in pancreatic cancer, colon cancer and gastric cancer that identify novel biomarkers and genetic profile patterns that are predictive of therapeutic response. Results of these studies will be presented during the 2008 American Society of Clinical Oncology...

  Articles 2008-05-29

• Response Genetics, Inc. to Present Multiple Studies at the 2008 American Society of Clinical Oncology Annual Meeting Confirming Positive Results for ResponseDX™ Tests

  Data Support the Use of ERCCI and TS Gene Expression to Predict the Effectiveness of Chemotherapy Treatment in Colon, Non-Small Cell Lung and Ovarian Cancers LOS ANGELES -- Response Genetics, Inc. (Nasdaq:RGDX) will announce the results of studies that support the validity of using the molecular markers, excision...

  Articles 2008-05-29

• Response Genetics, Inc. Reports First Quarter 2008 Financial Results

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2008. "These results, coupled with our expansion of the ResponseDX: Lung[TM] and ResponseDX:...

  Articles 2008-05-15

• Response Genetics, Inc. to Release First Quarter 2008 Financial Results and Present at the Rodman & Renshaw Fifth Annual Global Healthcare Conference

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX) will announce first quarter 2008 financial results in a press release Thursday, May 15 after close of market. Response Genetics, Inc. also announced today that Kathleen Danenberg, President and CEO of Response Genetics, Inc., will present at the Rodman &...

  Articles 2008-05-13

• Response Genetics, Inc. Announces the Appointment of David Gandara, M.D. to Its Board of Directors

  Dr. Gandara is a Well-Known Expert in Lung Cancer and Developmental Therapeutics LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, announced today the appointment of David Gandara, M.D. to its Board of Directors. Dr. Gandara, a...

  Articles 2008-05-08

• Response Genetics, Inc. Announced Results of Pre-Clinical Studies on Gene Expression at the American Association for Cancer Research 2008 Annual Meeting

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, presented several pre-clinical studies at the American Association for Cancer Research AACR 2008 Annual Meeting in San Diego, April 12-16. Kathleen Danenberg, CEO and President of Response Genetics, Inc., co-presented...

  Articles 2008-04-16

• Response Genetics, Inc. Appoints John Ferrara to Its Board of Directors

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, announced today that John C. Ferrara has joined its Board of Directors. Mr. Ferrara is currently the Chief Financial Officer CFO for EDGAR[R] Online[R], Inc. (NASDAQ: EDGR) a...

  Articles 2008-04-10

• Response Genetics Reports Full Year 2007 and Fourth Quarter Financial Results

  Conference Call Today at 5 p.m. ET LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX) a company focused on the development of molecular diagnostic tests for cancer, today announced its consolidated financial results for the twelve months ended December 31, 2007 and the fourth quarter of 2007. ...

  Articles 2008-03-26

• Response Genetics, Inc. Announces Year-End 2007 Financials and Strategic Update Conference Call

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX) will announce year-end 2007 financial results in a press release at 4 p.m. ET on Wednesday, March 26 and will follow with an annual strategic update during a conference call scheduled for 5 p.m. ET on Wednesday, March 26. To...

  Articles 2008-03-20

• Weekly top gainers

  WEEKLY TOP GAINERSTOP TEN GAINERS BY PERCENTAGE March 12 March 5 ...

  Articles 2008-03-17

• Response Genetics, Inc. Launches ResponseDX™ Tests to Select Institutions

  Appoints New Vice President, Sales and Marketing Annual Strategic Update Conference Call Scheduled LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX) announced today that its ResponseDX: Lung[TM] and ResponseDX: Colon[TM] tests are now available to select medical institutions and practice groups through its CLIA-registered laboratory. ResponseDX:...

  Articles 2008-03-05

• Response Genetics, Inc. Presents at ROTH 20th Annual OC Growth Stock Conference

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ:RGDX) today announced its President and CEO, Kathleen Danenberg, will provide a business overview, including an update on its ResponseDX[TM] PCR-based genetic tests, at the ROTH 20th Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel, in Dana Point, California February 18-21....

  Articles 2008-02-19

• Response Genetics, Inc. to Perform the MAGE-A3 Screening Assay for the Current GlaxoSmithKline Phase III Novel MAGE-A3 Cancer Immunotherapeutic in Non-Small Cell Lung Cancer

  LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX) today announced that it has begun performing the MAGE-A3 gene expression screening assay for GlaxoSmithKline's GSK Phase III clinical trial of the investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic ASCI as adjuvant therapy in MAGE-A3 positive patients with stage IB, II or IIIA Non-Small...

  Articles 2008-01-22

• Weekly top gainers

  WEEKLY TOP GAINERSTOP TEN GAINERS BY PERCENTAGE Nov. 7 Oct. 31 PriceCompany Close ...

  Articles 2007-11-12